|
|
|
Insider
Information: |
Rocklage Scott M |
Relationship: |
10% Owner |
City: |
|
State: |
|
|
|
Insider
Summary: |
|
|
|
Companies Owned : |
9 |
|
Direct
Shares |
0 |
|
Indirect Shares
|
27,883,627 |
|
|
Direct
Value |
$0 |
|
|
Indirect Value
|
$108 |
|
|
Total
Shares |
27,883,627 |
|
|
Total
Value |
$108 |
|
|
|
|
|
|
|
|
Historical
Performance :
Based on 6 Month Return Percentages |
Buys
|
Sells
|
Total
Filings :
|
0
|
0
|
Stock
price went up :
|
0
|
0
|
Stock
price went down : |
0
|
0
|
|
|
|
Gain/Loss Ratio : |
0.0
|
0.0
|
Percentage
Gain/Loss : |
0.0%
|
0.0%
|
|
|
|
|
|
|
Holdings
:
Menu |
Company Name |
Ticker |
Relation |
Direct Date |
Direct Shares |
Indirect Date |
Indirect Shares |
Total Value Sold |
|
Relypsa Inc |
RLYP |
Director, 10% Owner |
|
0 |
2013-11-20 |
62,316 |
Premium* |
|
Epirus Biopharmaceuticals Inc |
EPRS |
Director, 10% Owner |
|
0 |
2015-02-04 |
2,549,211 |
Premium* |
|
Vive Medical Inc |
VIVE |
10% Owner |
2015-05-14 |
0 |
2015-05-14 |
288,447 |
Premium* |
|
Pulmatrix Inc |
PULM |
Director |
2015-06-15 |
0 |
2015-06-16 |
168,873 |
Premium* |
|
Scpharmaceuticals Inc. |
SCPH |
10% Owner |
2017-11-21 |
0 |
2017-11-21 |
130,135 |
Premium* |
|
Aprea Therapeutics, Inc. |
APRE |
Former 10% holder |
|
0 |
2020-10-05 |
2,037,654 |
Premium* |
|
Ideaya Biosciences, Inc. |
IDYA |
10% Owner |
2020-11-11 |
0 |
2020-11-11 |
384,496 |
Premium* |
|
Rallybio Corp |
RLYB |
10% Owner |
2021-08-02 |
0 |
2023-03-07 |
3,630,724 |
Premium* |
|
Pear Therapeutics, Inc |
PEAR |
10% Owner |
|
0 |
2021-12-03 |
18,631,771 |
Premium* |
|
|
|
|
|
|
|
|
|
|
Records found :
25 |
Free Registration Required For Full Results. Limit: 25
|
|
Download |
Page 2 of 1
|
25 Records found
|
|
Page 2 of 1 |
|
Free Registration Required For Full Results. Limit: 25
|
|
|
Transaction Code Key: |
Ownership Code Key |
|
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
|
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Aquired |
|
IO |
- Initital Ownership |
D |
- Disposed |
|
|
|
|
|
|